RICTOR and triple-negative breast carcinoma: Overexpression of Rictor frequently occurs in human cancers, and RICTOR amplification has been identified in breast cancer, residual triple negative breast cancers following neoadjuvant therapy and lung adenocarcinomas with mTORC1/2-inhibitor susceptibility [44–46].